Pharmacopsychiatry 2000; 33(Suppl 1): 14-33
DOI: 10.1055/s-2000-7672
Review
ORIGINALARBEIT
© Georg Thieme Verlag Stuttgart · New York

Tardive Drug-Induced Extrapyramidal Syndromes

M. Maršálek
  • Mental Hospital Prague Bohnice, Prague, Czech Republic
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
 

The clinical features, outcomes, differential diagnoses, epidemiology, risk factors, and treatment approaches to tardive drug-induced extrapyramidal syndromes (EPS) are reviewed. Tardive forms of dyskinesia (TD), dystonia (TDt), akathisia (TA), Gilles de la Tourette syndrome (TGTS), myoclonus (TM), and parkinsonism (TP) are described. Moreover, pharmacological and topographical subtypes of TD are discussed. While TD, TDt, and TA are clearly delineated syndromes, there are limited data on TGTS, TM, and the questionable TP. TDt is distinguished from TD by clinical and treatment-related variables. Epidemiological studies provide evidence of better prognosis for TD compared with both TDt and TA. Two distinct groups of variables were found to be associated with a higher risk for TD: an exogenous factor (neuroleptic treatment variables and alcohol or drug abuse) and a factor of predisposition (elderly, female, affective disorder diagnosis, presence of EPS, diabetes mellitus type II, and signs of central vulnerability). In contrast, being younger and male was associated with TDt. A significant relationship between the hyperkinetic forms of tardive EPS was confirmed. Therapeutic strategy differs for the mild, moderate, and severe forms of tardive EPS. Using low doses of antipsychotics is a good preventive approach. Reducing the dose or switching to an atypical antipsychotic is the usual, but not yet fully explored, first therapeutic step. Clozapine, an antipsychotic with antidyskinetic and antidystonic effectiveness, is the second treatment step. Various suppressors of tardive movements were tested in controlled trials, mainly in TD. GABAergic benzodiazepines (clonazepam), adrenergic antagonists (propranolol, clonidine), antioxidants (α-tocopherol), and calcium channel blockers (nifedipine) are useful in the third step of treatment of more severe tardive EPS. Unlike TD, TDt and (partially) TA improve on higher doses of anticholinergic medication. Local injection of botulinum A toxin markedly ameliorates focal tardive dystonia over several months. Less verified therapeutic interventions are discussed.

References

  • 1 Adityanjee, Chan T M, Subramaniam M. Temporary remission of tardive dystonia following electroconvulsive therapy.  Br J Psychiatry. 1990;  156 433-435
    PubMedGoogle Scholar
  • 2 Andreassen O A, MacEwan T, Gulbrandsen A K, McCreadie R G, Steen V M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.  Psychopharmacology (Berlin). 1997;  131 174-179
    CrossrefPubMedGoogle Scholar
  • 3 American College of Neuropharmacology - Food and Drug Administration Task Force . Neurological syndromes associated with antipsychotic drug use.  Arch Gen Psychiatry. 1973;  28 463-467
    PubMedGoogle Scholar
  • 4 Armstrong M, Daly A K, Blennerhassett R, Ferrier N, Idle J R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.  Br J Psychiatry. 1997;  170 23-26
    PubMedGoogle Scholar
  • 5 Aronson T A. Persistent drug-induced parkinsonism.  Biol Psychiatry. 1985;  20 795-798
    CrossrefPubMedGoogle Scholar
  • 6 Arthur H, Dahl M L, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.  J Clin Psychopharmacol. 1995;  15 211-216
    PubMedGoogle Scholar
  • 7 Asnis G M, Leopold M A, Duvoisin R C, Schwartz A H. A survey of tardive dyskinesia in psychiatric outpatients.  Am J Psychiatry. 1977;  134 1367-1370
    PubMedGoogle Scholar
  • 8 Bailey L G, Maxwell S, Brandabur M M. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.  Psychopharmacol Bull. 1997;  33 177-181
    PubMedGoogle Scholar
  • 9 Baldessarini R J, Tarsy D. Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF, editors Psychopharmacology: A generation in progress. New York; 1st ed. Raven Press 1978: 993-1004
    Google Scholar
  • 10 Barnes T RE, Braude W M. Akathisia variants and tardive dyskinesia.  Arch Gen Psychiatry. 1985;  42 874-878
    PubMedGoogle Scholar
  • 11 Barnes T RE, Kidger T, Gore S M. Tardive dyskinesia: a 3-year follow-up study.  Psychol Med. 1983;  13 71-81
    PubMedGoogle Scholar
  • 12 Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.  Biol Psychiatry. 1992;  32 580-594
    CrossrefPubMedGoogle Scholar
  • 13 Bharucha K J, Sethi K D. Tardive tourettism after exposure to neuroleptic therapy.  Mov Disord. 1995;  10 791-793
    CrossrefPubMedGoogle Scholar
  • 14 Bobruff A, Gardos G, Tarsy D, Rapkin R M, Cole J O, Moore P. Clonazepam and phenobarbital in tardive dyskinesia.  Am J Psychiatry. 1981;  138 189-193
    PubMedGoogle Scholar
  • 15 Braun V, Richter H P. Selective peripheral denervation for the treatment of spasmodic torticollis.  Neurosurgery. 1994;  35 58-62
    PubMedGoogle Scholar
  • 16 Braude W M, Barnes T RE, Gore S M. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admission.  Br J Psychiatry. 1983;  143 139-150
    PubMedGoogle Scholar
  • 17 Brown K W, White T. Pseudoakathisia and schizophrenic negative symptoms.  Acta Psychiatr Scand. 1991;  84 107-109
    PubMedGoogle Scholar
  • 18 Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan E O. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia.  Acta Psychiatr Scand. 1996;  94 118-124
    CrossrefPubMedGoogle Scholar
  • 19 Burke R E. Tardive akathisia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 409-424
    Google Scholar
  • 20 Burke R E, Fahn S, Jankovic J, Marsden C D, Lang A E, Gollomp S, Illson J. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.  Neurology. 1982;  32 1335-1346
    CrossrefPubMedGoogle Scholar
  • 21 Burke R E, Kang U J, Jankovic J, Miller L G, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trial.  Mov Disord. 1989;  4 157-175
    CrossrefPubMedGoogle Scholar
  • 22 Cadet J L, Lohr J B, Jeste D V. Free radicals and tardive dyskinesia (letter).  Trends Neurosci. 1986;  9 107-108
    CrossrefPubMedGoogle Scholar
  • 23 Caine E D, Polin R J, Kartzinel R, Ebert M H. The trial use of clozapine for abnormal involuntary movement disorders.  Am J Psychiatry. 1979;  136 317-320
    PubMedGoogle Scholar
  • 24 Caracci G, Mukherjee S, Roth S D, Decina P. Subjective awareness of abnormal involuntary movements in chronic schizophrenic patients.  Am J Psychiatry. 1990;  147 295-298
    PubMedGoogle Scholar
  • 25 Carroll B J, Curtis J, Komken E. Paradoxical response to dopamine agonists in tardive dyskinesia.  Am J Psychiatry. 1977;  137 785-789
    PubMedGoogle Scholar
  • 26 Casey D E. Spontaneous and tardive dyskinesias: clinical and laboratory studies.  J Clin Psychiatry. 1985;  46 42-47
    PubMedGoogle Scholar
  • 27 Casey D E. Affective disorder and tardive dyskinesia.  Encephale. 1988;  14 221-226
    PubMedGoogle Scholar
  • 28 Casey D E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia.  Psychopharmacol Bull. 1989;  99 S47-S53
    PubMedGoogle Scholar
  • 29 Casey D E, Denney D. Pharmacological characterization of tardive dyskinesia.  Psychopharmacology. 1977;  54 1-8
    CrossrefPubMedGoogle Scholar
  • 30 Casey D E, Gardos G. Tardive dyskinesia: outcome at 10 years.  Schizophr Res. 1990;  3 11
    PubMedGoogle Scholar
  • 31 Casey D E, Hansen T E. Spontaneous dyskinesia. In: Jeste DV, Wyatt RJ, editors Neuropsychiatric movement disorders. Washington (DC); 1st ed. American Psychiatric Press 1984: 68-95
  • 32 Casey D E, Rabins P. Tardive dyskinesia as a life-threatening illness.  Am J Psychiatry. 1978;  135 486
    PubMedGoogle Scholar
  • 33 Chakos M H, Alvir J M, Woerner M G, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane J M, Borenstein M, Lieberman J A. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.  Arch Gen Psychiatry. 1996;  53 313-319
    PubMedGoogle Scholar
  • 34 Chiu H F, Leung J, Li K W. Tardive dystonia and diffuse idiopathic skeletal hyperostosis.  Singapore Med J. 1991;  32 94-95
    PubMedGoogle Scholar
  • 35 Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian Multicentre Risperidone Study.  J Clin Psychopharmacol. 1995;  15 (suppl 1) 36-44
    PubMedGoogle Scholar
  • 36 Chouinard G, Annable L, Ross-Chouinard A, Nestoros J N. Factors related to tardive dyskinesia.  Am J Psychiatry. 1979;  136 79-83
    PubMedGoogle Scholar
  • 37 Chouinard G, Boisvert D, Bradwejn J. Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug.  Can Med Assoc J. 1982;  126 821-827
    PubMedGoogle Scholar
  • 38 Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five year follow-up study of tardive dyskinesia.  Psychopharmacol Bull. 1986;  22 259-263
    PubMedGoogle Scholar
  • 39 Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.  J Clin Psychopharmacol. 1988;  8 (suppl 4) 21S-26S
    PubMedGoogle Scholar
  • 40 Cohen B M, Keck P E, Satlin A, Cole J O. Prevalence and severity of akathisia in patients on clozapine.  Biol Psychiatry. 1991;  29 1215-1219
    CrossrefPubMedGoogle Scholar
  • 41 Cole J O, Gardos G, Boling L A, Marby D, Haskell D, Moore P. Early dyskinesia - vulnerability.  Psychopharmacology. 1992;  107 503-510
    PubMedGoogle Scholar
  • 42 Crane G E. Persistence of neurological symptoms due to neuroleptic.  Am J Psychiatry. 1971;  127 1407-1410
    PubMedGoogle Scholar
  • 43 Crane G E. Persistent dyskinesia.  Br J Psychiatry. 1973;  122 395-405
    PubMedGoogle Scholar
  • 44 Crane G E, Naranjo E R. Motor disorders induced by neuroleptics. (A proposal new classification).  Arch Gen Psychiatry. 1971;  24 179-184
    PubMedGoogle Scholar
  • 45 Dave M. Clozapine-related tardive dyskinesia.  Biol Psychiatry. 1994;  35 886-887
    CrossrefPubMedGoogle Scholar
  • 46 DeKeyser J, D'Haenen H. Disappearance of akathisia following electroconvulsive treatment.  Clin Neuropharmacol. 1986;  9 563-565
    PubMedGoogle Scholar
  • 47 Dixon L, Weiden P, Haag G, Sweeney J, Frances A J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients.  Compr Psychiatry. 1992;  33 121-122
    CrossrefPubMedGoogle Scholar
  • 48 Egan M F, Apud J, Wyatt R J. Treatment of tardive dyskinesia.  Schizophr Bull. 1997;  23 583-609
    PubMedGoogle Scholar
  • 49 Engelhardt D M, Polizos P, Waizer J. CNS consequences of psychotropic drug withdrawal in autistic children: a follow-up report.  Psychopharmacol Bull. 1975;  11 6-7
    PubMedGoogle Scholar
  • 50 Factor S A, Friedman J H. The emerging role of clozapine in the treatment of movement disorders.  Mov Disord. 1997;  12 483-496
    CrossrefPubMedGoogle Scholar
  • 51 Fahn S. High-dose anticholinergic therapy in dystonia.  Neurology. 1983;  33 1255-1261
    CrossrefPubMedGoogle Scholar
  • 52 Fahn S. A therapeutic approach to tardive dyskinesia.  J Clin Psychiatry. 1985;  46 19-24
    PubMedGoogle Scholar
  • 53 Fahn S, Marsden D, van Woert M H. Definition and classification of myoclonus.  Adv Neurol.. 1986;  43 1-5
    PubMedGoogle Scholar
  • 54 Fann W E, Stafford J E, Malone R L, Frost J D, Richman B W. Clinical research techniques in tardive dyskinesia.  Am J Psychiatry. 1977;  134 759-762
    PubMedGoogle Scholar
  • 55 Faurbye A, Rasch P J, Peterson P B, Brandborg G, Pakkenberg G. Neurological symptoms in pharmacotherapy of psychoses.  Acta Psychiatr Scand. 1964;  40 10-27
    PubMedGoogle Scholar
  • 56 Feltner D E, Hertzman M. Progress in the treatment of tardive dyskinesia: theory and practice.  Hospital and Community Psychiatry. 1993;  44 25-34
    PubMedGoogle Scholar
  • 57 Fibiger H C, Lloyd K G. Neurobiological substances of tardive dyskinesia: the GABA hypothesis.  Trends Neurosci. 1984;  7 462-464
    CrossrefPubMedGoogle Scholar
  • 58 Fitzgerald P M, Jankovic J. Tardive oculogyric crises.  Neurology. 1989;  39 1434-1437
    PubMedGoogle Scholar
  • 59 Fleischhacker W W, Miller C H, Barnas C, Bergmann K, Perovich R, Alvir J M, Lieberman J A, Kane J M. The effect of activation procedures on neuroleptic-induced akathisia.  Br J Psychiatry. 1993;  163 781-784
    PubMedGoogle Scholar
  • 60 Friedman J H, Kucharski L T, Wagner R L. Tardive dystonia in a psychiatric hospital.  J Neurol Neurosurg Psychiatry. 1987;  50 801-803
    PubMedGoogle Scholar
  • 61 Friis T, Christensen T R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism, and hyperkinesia.  Acta Psychiatr Scand. 1983;  67 178-187
    PubMedGoogle Scholar
  • 62 Fukuzako H, Tominaga H, Izumi K, Koja T, Nomoto M, Hokazono Y, Kamei K, Fujii H, Fukuda T, Matsumoto K. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients.  Biol Psychiatry. 1990;  27 1116-1126
    CrossrefPubMedGoogle Scholar
  • 63 Ganzini L, Casey D E, Hoffman W F, Heintz R T. Tardive dyskinesia and diabetes mellitus.  Psychopharmacol Bull. 1992;  28 281-286
    PubMedGoogle Scholar
  • 64 Gardos G. A case of withdrawal dyskinesia.  Am J Psychiatry. 1979;  136 1099
    PubMedGoogle Scholar
  • 65 Gardos G, Cole J O. Tardive dyskinesia and anticholinergics drugs.  Am J Psychiatry. 1983;  140 200-202
    PubMedGoogle Scholar
  • 66 Gardos G, Cole J O. The evaluation and treatment of neuroleptic-induced movement disorders.  Harvard Rev Psychiatry. 1995;  3 130-139
    PubMedGoogle Scholar
  • 67 Gardos G, Cole J O. Tardive dyskinesia and affective disorder. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 69-81
    Google Scholar
  • 68 Gardos G, Cole J O, LaBrie R A. Drug variables in the etiology of tardive dyskinesia: application of discriminant function analysis.  Prog Neuropsychopharmacol. 1977;  1 147-154
    PubMedGoogle Scholar
  • 69 Gardos G, Cole J O, Schniebolk S, Salomon M. Comparison of severe and mild tardive dyskinesia: implication for etiology.  J Clin Psychiatry. 1987a;  48 359-362
    PubMedGoogle Scholar
  • 70 Gardos G, Cole J O, Salomon M, Schniebolk S. Clinical forms of severe tardive dyskinesias.  Am J Psychiatry. 1987b;  144 895-902
    PubMedGoogle Scholar
  • 71 Gardos G, Cole J O, Haskell D, Marby D, Paine S S, Moore P. The natural history of tardive dyskinesia.  J Clin Psychopharmacol. 1988;  8 (suppl 4) 31S-37S
    PubMedGoogle Scholar
  • 72 Gardos G, Casey D E, Cole J O, Perényi A, Kocsis E, Arato M, Samson J A, Conley C. Ten-year outcome of tardive dyskinesia.  Am J Psychiatry. 1994;  151 836-841
    PubMedGoogle Scholar
  • 73 Gerlach J. Relationship between tardive dyskinesia, L-dopa-induced hyperkinesia and parkinsonism.  Psychopharmacology. 1977;  51 259-263
    CrossrefPubMedGoogle Scholar
  • 74 Gerlach J, Casey D E. Tardive dyskinesia.  Acta Psychiatr Scand. 1988;  77 369-378
    PubMedGoogle Scholar
  • 75 Gerlach J, Peacock L. Intolerance to neuroleptic drugs: the art of avoiding extrapyramidal syndromes.  Eur Psychiatry. 1995;  10 (suppl 1) 27-31
    CrossrefPubMedGoogle Scholar
  • 76 Gerlach J, Koppelhus E, Helweg E, Monrad A. Clozapine and haloperidol in a single-blind crossover trial: therapeutic and biochemical aspects in the treatment of schizophrenia.  Acta Psychiatr Scand. 1974;  50 410-424
    PubMedGoogle Scholar
  • 77 Gibb W R, Lees A J. The clinical phenomenon of akathisia.  J Neurol Neurosurg Psychiatry. 1986;  49 861-866
    PubMedGoogle Scholar
  • 78 Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe dyskinesia.  Acta Psychiatr Scand. 1985;  71 488-494
    PubMedGoogle Scholar
  • 79 Glazer W M, Morgenstern H, Niedzwiecki D, Hughes J. Heterogeneity of tardive dyskinesia: a multivariate analysis.  Br J Psychiatry. 1988;  152 253-259
    PubMedGoogle Scholar
  • 80 Glazer W M, Morgenstern H, Doucette J T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.  J Clin Psychiatry. 1993;  54 133-139
    PubMedGoogle Scholar
  • 81 Godwin-Austen R B, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine.  BMJ. 1971;  4 25-26
    PubMedGoogle Scholar
  • 82 Granacher R P Jr. Differential diagnosis of tardive dyskinesia: an owerview.  Am J Psychiatry. 1981;  130 1288-1297
    PubMedGoogle Scholar
  • 83 Greene P. Tardive dystonia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 395-408
    Google Scholar
  • 84 Greil W, Haag H, Rossangl G. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study.  Br J Psychiatry. 1984;  145 304-310
    CrossrefPubMedGoogle Scholar
  • 85 Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients less than 60 years of age.  J Neurol Neurosurg Psychiatry. 1988;  51 1225-1230
    PubMedGoogle Scholar
  • 86 Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors.  Psychol Med (London). 1989;  19 121-128
    PubMedGoogle Scholar
  • 87 Hallet M, Chadwick D, Marsden C D. Cortical reflex myoclonus.  Neurology. 1979;  29 1107-1125
    PubMedGoogle Scholar
  • 88 Halstead S M, Barnes T RE, Speller J C. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.  Br J Psychiatry. 1994;  164 177-183
    PubMedGoogle Scholar
  • 89 Hamer R M. Tongue, arms, face movement enough to assess dyskinesia.  Clin Psychiatr News. 1982;  10 22
    PubMedGoogle Scholar
  • 90 Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia.  Convuls Ther. 1995;  11 271-274
    PubMedGoogle Scholar
  • 91 Hansen T E, Hoffman W F. Drug-induced parkinsonism. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1995: 341-380
    Google Scholar
  • 92 Hay D P, Hay L, Blackwell B, Spiro H R. ECT and tardive dyskinesia.  J Geriatr Psychiatry Neurol. 1990;  3 106-109
    PubMedGoogle Scholar
  • 93 Huang C C, Wang R IH, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.  Psychopharmacology. 1981;  73 359-362
    CrossrefPubMedGoogle Scholar
  • 94 Inada T, Ichikawa T, Kato Y. et al . A case of tardive akathisia.  Japan J Psychiatric Treat. 1988;  3 772-774
    PubMedGoogle Scholar
  • 95 Inada T, Yagi G, Kamijima K, Ohnishi K, Kamisada M, Takamiya M, Nakajima S, Rockhold R W. A statistical trial of subclassification for tardive dyskinesia.  Acta Psychiatr Scand. 1990;  82 404-407
    PubMedGoogle Scholar
  • 96 Jaffe E, Trémeau F, Sharif Z, Reider R. Clozapine in tardive Tourette syndrome.  Biol Psychiatry. 1995;  38 196-197
    CrossrefPubMedGoogle Scholar
  • 97 Jeste D V, Wyatt R D. In search of treatment for tardive dyskinesia: review of the literature.  Schizophr Bull. 1979;  5 251-293
    PubMedGoogle Scholar
  • 98 Jeste D V, Wyatt R D. Changing epidemiology of tardive dyskinesia: an overview.  Am J Psychiatry. 1981;  138 297-309
    PubMedGoogle Scholar
  • 99 Jeste D V, Wyatt R D. Understanding and treating tardive dyskinesia. New York; 1st ed. Guilford Press 1982
  • 100 Jeste D V, Potkin S G, Sinha S, Feder S, Wyatt R J. Tardive dyskinesia - reversible and persistent.  Arch Gen Psychiatry. 1979;  36 585-590
    PubMedGoogle Scholar
  • 101 Jeste D V, Lohr J B, Clark K, Wyatt R J. Pharmacological treatments of tardive dyskinesia in the 1980s.  J Clin Psychopharmacol. 1988;  8(suppl 4) 38S-48S
    PubMedGoogle Scholar
  • 102 Jeste D V, Caligiuri M P, Paulsen J S, Heaton R K, Lacro J P, Harris M J, Bailey A, Fell R L, McAdams L A. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.  Arch Gen Psychiatry. 1995;  52 756-765
    PubMedGoogle Scholar
  • 103 Kabeš J, Sikora J, Pišvejc J, Star¿ O. Subchronic administration of piracetam in tardive dyskinesia - placebo controlled cross-over comparison.  Activ Nerv Super (Prague). 1985;  27 63-64
    PubMedGoogle Scholar
  • 104 Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine.  J Nerv Ment Dis. 1993;  181 649-651
    PubMedGoogle Scholar
  • 105 Kane J M, Smith J M. Tardive dyskinesia. Prevalence and risk factors, 1959 - 1979.  Arch Gen Psychiatry. 1982;  39 473-481
    CrossrefPubMedGoogle Scholar
  • 106 Kane J M, Wegner J, Stenzler S, Pamsey P. The prevalence of presumed tardive dyskinesia in psychiatric in-patients and out-patients.  Psychopharmacology. 1980;  69 247-251
    CrossrefPubMedGoogle Scholar
  • 107 Kane J M, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia.  Psychopharmacol Bull. 1986;  22 254-258
    PubMedGoogle Scholar
  • 108 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors.  J Clin Psychopharmacol. 1988;  8(Aug suppl) 52S-56S
    PubMedGoogle Scholar
  • 109 Kang U J, Burke R E, Fahn S. Natural history and treatment of tardive dystonia.  Mov Disord. 1986;  1 193-208
    CrossrefPubMedGoogle Scholar
  • 110 Karagianis J L, Nagpurkar R. A case of Tourette syndrome developing during haloperidol treatment.  Can J Psychiatry. 1990;  35 228-232
    PubMedGoogle Scholar
  • 111 Karson K N, Jeste D V, LeWitt P A, Wyatt R J. A comparison of two iatrogenic dyskinesias.  Am J Psychiatry. 1984;  140 1504-1506
    PubMedGoogle Scholar
  • 112 Kaufmann C A, Jeste D V, Shelton R C, Linnoila M, Kafka M S, Wyatt R J. Noradrenergic and neuroradiological abnormalities in tardive dyskinesia.  Biol Psychiatry. 1986;  21 799-812
    CrossrefPubMedGoogle Scholar
  • 113 Kazamatzuri H, Chien C-P, Cole J O. Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.  Arch Gen Psychiatry. 1972;  27 95-99
    PubMedGoogle Scholar
  • 114 Kazamatzuri H, Chien C-P, Cole J O. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.  Am J Psychiatry. 1973;  130 479-483
    PubMedGoogle Scholar
  • 115 Keegan D I, Rajput A H. Drug-induced dystonia tarda - treatment with L-dopa.  Dis Nerv Syst. 1973;  38 167-169
    PubMedGoogle Scholar
  • 116 Keepers G A, Casey D E. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.  Am J Psychiatry. 1991;  148 85-89
    PubMedGoogle Scholar
  • 117 Kidger T, Barnes T R E, Trauer T, Taylor P J. Sub-syndromes of tardive dyskinesia.  Psychol Med (London). 1980;  10 19-20
    PubMedGoogle Scholar
  • 118 Klawans H L. The pharmacology of tardive dyskinesia.  Am J Psychiatry. 1973;  130 82-86
    PubMedGoogle Scholar
  • 119 Klawans H L Jr, Bergen D, Bruyn G W. Prolonged drug-induced parkinsonism.  Confinia Neurologica. 1973;  35 368-377
    PubMedGoogle Scholar
  • 120 Klawans H L, Falk D K, Nausieda P A, Weiner W J. Gilles de la Tourette syndrome after long term chlorpromazine therapy.  Neurology. 1978;  28 1064-1068
    CrossrefPubMedGoogle Scholar
  • 121 Klawans H L, Tanner C M, Barr A. The reversibility of “permanent” tardive dyskinesia.  Clin Neuropharmacol. 1984;  7 153-159
    CrossrefPubMedGoogle Scholar
  • 122 Klawans H L, Curvey P M, Tanner C M, Goetz C G. Drug-induced myoclonus. In: Fahn S, Marsden CD, van Woert MH, editors Advances in neurology. Vol 43. 1st ed. New York: Raven Press 1986: 251-264
    Google Scholar
  • 123 Ko G N, Zhang L D, Yan W W, Zhang M D, Buchner D, Xia Z Y, Wyatt R J, Jeste D V. The Shanghai 800: prevalence of tardive dyskinesia in a chinese psychiatric hospital.  Am J Psychiatry. 1989;  146 387-389
    PubMedGoogle Scholar
  • 124 Kobayashi R M. Drug therapy of tardive dyskinesia.  N Engl J Med. 1977;  296 257-260
    PubMedGoogle Scholar
  • 125 Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of three cases.  Am J Psychiatry. 1960;  117 152-153
    PubMedGoogle Scholar
  • 126 Kucharski L T, Smith J W, Dunn D D. Mortality and tardive dyskinesia.  Am J Psychiatry. 1978;  135 1228
    PubMedGoogle Scholar
  • 127 Kuniyoshi M, Inanaga K, Arikawa K, Maeda Y, Nakamura J, Uchimura N. A case of tardive Tourette-like syndrome.  Jpn J Psychiatry Neurol. 1992;  46 67-70
    PubMedGoogle Scholar
  • 128 Kurz M, Hummer M, Oberbauer H, Fleischhacker W W. Extrapyramidal side-effects of clozapine and haloperidol.  Psychopharmacology. 1995;  118 52-56
    PubMedGoogle Scholar
  • 129 Lauciello F, Appelbaum M. Prosthodontic implications of tardive dyskinesia.  NY State Dent J. 1977;  43 214-217
    PubMedGoogle Scholar
  • 130 Lazarus A L, Toglia J U. Fatal myoglobinuric renal failure in a patient with tardive dyskinesia.  Neurology. 1985;  35 1055-1057
    PubMedGoogle Scholar
  • 131 Lieberman J A, Lesser M, Johns C, Pollack S, Saltz B, Kane J M. Pharmacological studies of tardive dyskinesia.  J Clin Psychopharmacol. 1988a;  8 (suppl) 57-63
    PubMedGoogle Scholar
  • 132 Lieberman J A, Pollack S, Lesser M, Kame J M. Pharmacological characterization of tardive dyskinesia.  J Clin Psychopharmacol. 1988b;  8 254-260
    PubMedGoogle Scholar
  • 133 Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J M. The effect of clozapine on tardive dyskinesia.  Br J Psychiatry. 1991;  158 503-510
    PubMedGoogle Scholar
  • 134 Little J T, Jankovic J. Tardive myoclonus.  Mov Disord. 1987;  2 307-312
    CrossrefPubMedGoogle Scholar
  • 135 Mackay A V P, Sheppard G G. Pharmacotherapeutic trials in tardive dyskinesia.  Br J Psychiatry. 1979;  135 489-499
    PubMedGoogle Scholar
  • 136 Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.  Am J Psychiatry. 1981;  138 184-188
    PubMedGoogle Scholar
  • 137 Maršálek M. Do antidepressants increase risk of suicide?.  CS Psychiat. 1998;  94 272-281
    PubMedGoogle Scholar
  • 138 Maršálek M, Roth Z. Subtypes of tardive dyskinesia.  Clin Neuropsychopharmacol. 1992;  15 (suppl 1) 268 B
    PubMedGoogle Scholar
  • 139 McClelland H A, Dutta D, Metcalf A, Kerr T A. Mortality and facial dyskinesia.  Br J Psychiatry. 1986;  148 310-316
    PubMedGoogle Scholar
  • 140 McCreadie R G, Robertson L J, Wiles D H. The Nisthsdale Schizophrenia Surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.  Br J Psychiatry. 1992;  161 793-799
    PubMedGoogle Scholar
  • 141 Meltzer H Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient.  Schizophr Bull. 1992;  18 515-542
    PubMedGoogle Scholar
  • 142 Miller L G, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients.  South Med J. 1990;  83 525-532
    CrossrefPubMedGoogle Scholar
  • 143 Moore D C, Bowers M B Jr. Identification of a tardive dyskinesia patients by pharmacologic probes.  Am J Psychiatry. 1980;  137 1202-1205
    PubMedGoogle Scholar
  • 144 Morgenstern H, Glazer W M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications.  Arch Gen Psychiatry. 1993;  50 723-733
    PubMedGoogle Scholar
  • 145 Morgenstern H, Glazer W M, Gibowski L D, Holmbey S. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatients population.  J Chronic Dis. 1987;  40 319-327
    CrossrefPubMedGoogle Scholar
  • 146 Mueller J, Aminoff M J. Tourette-like syndrome after long-term neuroleptic treatment.  Br J Psychiatry. 1982;  141 191-193
    PubMedGoogle Scholar
  • 147 Mukherjee S, Mahadik S P. Diabetes mellitus and tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 82-98
    Google Scholar
  • 148 Mukherjee S, Bilder R M, Sakeim H A. Tardive dyskinesia and glucose metabolism (letter).  Arch Gen Psychiatry. 1986a;  43 192-193
    PubMedGoogle Scholar
  • 149 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatry. 1986b;  43 342-346
    PubMedGoogle Scholar
  • 150 Myslobodsky M S, Holden T, Sandler R. Asymmetry of abnormal involuntary movements: a prevalence study.  Biol Psychiatry. 1984;  19 623-628
    PubMedGoogle Scholar
  • 151 Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients.  Psychopharmacology. 1989;  99 S73-S76
    CrossrefPubMedGoogle Scholar
  • 152 Nelli A C, Yarden P E, Guazelli M, Feinberg I. Parkinsonism following neuroleptic withdrawal (letter).  Arch Gen Psychiatry. 1989;  46 383-384
    PubMedGoogle Scholar
  • 153 Olivera A A, Kiefer M W, Manley N K. Tardive dyskinesia in psychiatric patients with substance use disorders.  Am J Drug Alcohol Abuse. 1990;  16 57-66
    PubMedGoogle Scholar
  • 154 Osborne T E, Grace E G, Schwartz M K. Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: a literature review and case report.  J Craniomandib Pract. 1989;  7 58-62
    PubMedGoogle Scholar
  • 155 Owens D G C. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge; 1st ed. Cambridge University Press 1999
  • 156 Owens D G C, Johnstone E C, Frith C M. Spontaneous involuntary disorders of movement.  Arch Gen Psychiatry. 1982;  39 452-461
    PubMedGoogle Scholar
  • 157 Ozelius L, Kramer P L, Moskowitz C B, Kwiatkowski D J, Brin M F, Bressman S B, Schuback D E, Falk C T, Risch N, de Leon D, Burke R E, Haines J, Gusella J F, Fahn S, Breakefield X O. Human gene for torsion dystonia located on chromosome 9q32-34.  Neuron. 1989;  2 1427-1434
    CrossrefPubMedGoogle Scholar
  • 158 Paulsen J S, Caligiuri M P, Palmer B, McAdams L A, Jeste D V. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.  Psychopharmacology (Berlin). 1996;  123 307-314
    PubMedGoogle Scholar
  • 159 Polizos P, Engelhardt D M, Hoffman S P. Neurological consequences of psychotropic drug withdrawal in schizophrenic children.  J Autism Child Schizo. 1973;  3 247-253
    PubMedGoogle Scholar
  • 160 Postolache T T, Londono J H, Halem R G, Newmark M D. Electroconvulsive therapy in tardive dystonia.  Convuls Ther. 1995;  11 275-279
    PubMedGoogle Scholar
  • 161 Povlsen U J, Noring U, Fog R. Tolerability and therapeutic effect of clozapine.  Acta Psychiatr Scand. 1985;  71 176-185
    PubMedGoogle Scholar
  • 162 Quitkin F, Rifkin R, Gouchfeld L, Klein D F. Tardive dyskinesia: Are first signs reversible?.  Am J Psychiatry. 1977;  134 84-87
    PubMedGoogle Scholar
  • 163 Raja M. Tardive dystonia: prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients.  Eur Arch Psychiatry Clin Neurosci. 1995;  245 145-151
    PubMedGoogle Scholar
  • 164 Richardson M A, Haugland M A, Pass R, Craig T J. The prevalence of tardive dyskinesia in a mentally retarded population.  Psychopharmacol Bull. 1986;  22 243-249
    PubMedGoogle Scholar
  • 165 Richardson M A, Suckow R, Whittaker R, Boggiano W, Sziraki I, Kushner H, Perumal A. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia.   Psychopharmacol Bull. 1989;  25 47-51
    PubMedGoogle Scholar
  • 166 Ritchie E C, Bridenbaugh R H, Jabbari B. Acute generalized myoclonus following buspirone administration.  J Clin Psychiatry. 1988;  49 242-243
    PubMedGoogle Scholar
  • 167 Sachdev P. The prevalence of tardive dystonia in patients with chronic schizophrenia.  Aust N Z J Psychiatry. 1991;  25 446-448
    PubMedGoogle Scholar
  • 168 Sachdev P. Clinical characteristics of 15 patients with tardive dystonia.  Am J Psychiatry. 1993;  150 498-500
    PubMedGoogle Scholar
  • 169 Sachdev P. Akathisia and restless legs. Cambridge; 1st ed. Cambridge University Press 1995
  • 170 Sachdev P, Loneragan C. Intravenous challenges of benztropine and propranolol in tardive akathisia.  Psychopharmacology. 1993;  116 324-331
    PubMedGoogle Scholar
  • 171 Sachdev P, Hume F, Toohey P, Doutney C. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.  Acta Psychiatr Scand. 1996;  93 451-459
    PubMedGoogle Scholar
  • 172 Safferman A Z, Lieberman J A, Pollack S, Kane J M. Akathisia and clozapine treatment (letter).  J Clin Psychopharmacol. 1993;  13 286-287
    PubMedGoogle Scholar
  • 173 Sahoo R N, Mitra G C, Mohanty P C. Irreversible drug induced parkinsonism.  J Assoc Physicians India. 1975;  23 529-530
    PubMedGoogle Scholar
  • 174 Sajatovic M, Meltzer H Y. Clozapine-induced myoclonus and generalized seizures.   Biol Psychiatry. 1996;  39 367-370
    CrossrefPubMedGoogle Scholar
  • 175 Saltz B, Woerner M G, Kane J M, Lieberman J A, Alvir J M J, Bergmann K J, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia in the elderly.  JAMA. 1991;  266 2402-2406
    CrossrefPubMedGoogle Scholar
  • 176 Sandyk R, Derpapas H. Successful treatment of respiratory dyskinesia with picoTesla range magnetic fields.  Int J Neurosci. 1994;  75 91-102
    PubMedGoogle Scholar
  • 177 Sandyk R, Fisher H. Serotonin in involuntary movement disorders.  Int J Neurosci. 1988;  42 185-205
    PubMedGoogle Scholar
  • 178 Schmid W R, Jarcho L W. Persistent dyskinesias following phenothiazine treatment.  Arch Neurol. 1966;  14 369-377
    PubMedGoogle Scholar
  • 179 Schönecker M. Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.  Nervenarzt. 1957;  28 35
    PubMedGoogle Scholar
  • 180 Schooler N R, Kane J M. Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
    PubMedGoogle Scholar
  • 181 Schrodt G R, Wright J H, Simpson R, Moore D P, Chase S. Treatment of tardive dyskinesia with propranolol.  J Clin Psychiatry. 1982;  43 328-331
    PubMedGoogle Scholar
  • 182 Schultz S K, Arndt S, Ho B-C, Oliver S E, Andreasen N C. Impaired glucose tolerance and abnormal movements in patients with schizophrenia.  Am J Psychiatry. 1999;  156 640-642
    PubMedGoogle Scholar
  • 183 Seeman M V, Patel J, Pyke J. Tardive dyskinesia with Tourette-like syndrome.  J Clin Psychiatry. 1981;  42 357-358
    PubMedGoogle Scholar
  • 184 Sethi K D, Hess D C, Harp R J. Prevalence of dystonia in veterans on chronic antipsychotic therapy.  Mov Disord. 1990;  5 319-321
    CrossrefPubMedGoogle Scholar
  • 185 Sigwald J, Bouttier D, Raymond C, Piot C. Quatre cas de dyskinésie facio-bucco-linguo-masticatice a évolution prolongée secondaire à un traitement par les neuroleptiques.  Rev Neurol (Paris). 1959;  100 751-755
    PubMedGoogle Scholar
  • 186 Simpson G, Amuso D, Blair J H, Farkas T. Phenothiazine-produced extra-pyramidal system disturbance.  Arch Gen Psychiatry. 1964;  10 199-208
    PubMedGoogle Scholar
  • 187 Simpson G, Lee J M, Shivastava R K. Clozapine in tardive dyskinesia.  Psychopharmacology. 1978;  56 75-80
    CrossrefPubMedGoogle Scholar
  • 188 Singh M M, Becker R, Pitman R K, Nasrallah H A, Lal H, Dufresne R L, Weber S S, McCalley-Whitters M. Diazepam-induced changes in tardive dyskinesia: suggestion for a new conceptual model.  Biol Psychiatry. 1982;  17 729-742
    PubMedGoogle Scholar
  • 189 Small J G, Milstein V, Marhenke J D, Hall D D, Kellams J J. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis.  J Clin Psychiatry. 1987;  48 263-267
    PubMedGoogle Scholar
  • 190 Smith J M, Strizich M, Klass D. Drug history and tardive dyskinesia.  Am J Psychiatry. 1978;  135 1402-1403
    PubMedGoogle Scholar
  • 191 Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.  J Clin Psychiatry. 1997;  58 318-322
    PubMedGoogle Scholar
  • 192 Stacy M, Jankovic J. Tardive tremor.  Mov Disord. 1992;  7 53-57
    PubMedGoogle Scholar
  • 193 Stahl S M. Tardive Tourette syndrome in an autistic patient after long term neuroleptic administration.  Am J Psychiatry. 1980;  137 1267-1269
    PubMedGoogle Scholar
  • 194 Storey E, Lloyd J. Tardive tremor.  Mov Disord. 1997;  12 808-810
    CrossrefPubMedGoogle Scholar
  • 195 Sweet R A, Mulsant B H, Gupta B, Rifai A H, Pasternak R E, McEachran A, Zubenko G S. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.  Arch Gen Psychiatry. 1995;  52 478-486
    PubMedGoogle Scholar
  • 196 Szymanski S, Lieberman J A, Safferman A, Galkowski B. Rib fractures as an unusual complication of severe tardive dystonia (letter).  J Clin Psychiatry. 1993;  54 160
    PubMedGoogle Scholar
  • 197 Tamminga C A, Thaker G K, Moran M, Kakigi T, Gao X M. Clozapine in tardive dyskinesia: observations from human and animal model studies.  J Clin Psychiatry. 1994;  55 (9 suppl B) 102-106
    PubMedGoogle Scholar
  • 198 Tardive Dyskinesia .A Task Force Report of the American Psychiatric Association. Washington (DC); American Psychiatric Association 1992
    Google Scholar
  • 199 Tarsy D, Kaufman D, Sethi K D, Rivner M H, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia.  Clin Neuropharmacol. 1997;  20 90-93
    PubMedGoogle Scholar
  • 200 Thaker G K, Nguyen J A, Strauss M E, Jacobson R, Kaup B A, Tamminga C A. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.  Am J Psychiatry. 1990;  147 445-451
    PubMedGoogle Scholar
  • 201 Toenniessen L M, Casey D E, McFarland B H. Tardive dyskinesia in the aged. Duration of treatment relationship.  Arch Gen Psychiatry. 1985;  42 278-284
    PubMedGoogle Scholar
  • 202 Tollefson G D, Beasley C M Jr, Tamura R N, Tran P V, Potvin J H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.  Am J Psychiatry. 1997;  154 1248-1254
    PubMedGoogle Scholar
  • 203 Tominaga H, Fukuzako H, Izumi K, Koja T, Fukuda T, Fujii H, Matsumoto K, Sonoda H, Imamura K. Tardive myoclonus (letter).  Lancet. 1987;  8528 322
    PubMedGoogle Scholar
  • 204 van Harten P N, Matroos G E, Hoek H W, Kahn R S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao Extrapyramidal Syndromes Study I.  Schizophr Res. 1996;  19 195-203
    CrossrefPubMedGoogle Scholar
  • 205 van Harten P N, Hoek H W, Matroos G E, Koeter M, Kahn R S. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II.  Schizophr Res. 1997;  26 235-242
    CrossrefPubMedGoogle Scholar
  • 206 van Harten P N, Hoek H W, Matroos G E, Koeter M, Kahn R S. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III.  Am J Psychiatry. 1998;  155 565-567
    PubMedGoogle Scholar
  • 207 van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk?.  Acta Psychiatr Scand. 1997;  96 206-216
    PubMedGoogle Scholar
  • 208 Waddington J L, Youssef H A, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality.  Arch Gen Psychiatry. 1987;  44 907-912
    PubMedGoogle Scholar
  • 209 Waddington J L, O'Callaghan E, Larkin C. Schizophrenia, long-term neuroleptic treatment and mechanism of late-onset side effects.  Psychopharmacology. 1988;  96 (suppl) 29
    PubMedGoogle Scholar
  • 210 Waddington J L, Youssef H A, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia.  Psychol Med. 1990;  20 835-842
    PubMedGoogle Scholar
  • 211 Weetman J, Anderson I M, Gregory R P, Gill S S. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia (letter).  J Neurol Neurosurg Psychiatry. 1997;  63 554-556
    PubMedGoogle Scholar
  • 212 Wegner J C, Catalano F, Gibralter J, Kane J M. Schizophrenics with tardive dyskinesia - neuropsychological deficit and family psychopathology.  Arch Gen Psychiatry. 1985;  42 860-865
    PubMedGoogle Scholar
  • 213 Weiner W J, Luby E D. Tardive akathisia.  J Clin Psychiatry. 1983;  44 417-419
    PubMedGoogle Scholar
  • 214 Wilson J A, Smith R G. Relation between elderly and AIDS patients with drug-induced Parkinson's disease.  Lancet. 1987;  2 686
    PubMedGoogle Scholar
  • 215 Winsberg B G, Hurwic M J, Perel J. Neurochemistry of withdrawal emergent symptoms in children.  Psychopharmacol Bull. 1977;  13 38-40
    PubMedGoogle Scholar
  • 216 Wojcik J D, Falk W E, Fink J S, Cole J O, Gelenberg A J. A review of 32 cases of tardive dystonia.  Am J Psychiatry. 1991;  148 1055-1059
    PubMedGoogle Scholar
  • 217 Yadalam K G, Korn M L, Simpson G M. Tardive dystonia: four case histories.  J Clin Psychiatry. 1990;  51 17-20
    PubMedGoogle Scholar
  • 218 Yagi G, Itoh H. Follow-up study of 11 patients with potentially reversible tardive dyskinesia.  Am J Psychiatry. 1987;  144 1496-1498
    PubMedGoogle Scholar
  • 219 Yassa R. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions.  Acta Psychiatr Scand. 1989;  80 64-67
    PubMedGoogle Scholar
  • 220 Yassa R. Other factors in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 99-103
    Google Scholar
  • 221 Yassa R, Ananth J. Familial tardive dyskinesia.  Am J Psychiatry. 1981;  138 1618-1619
    PubMedGoogle Scholar
  • 222 Yassa R, Jeste D V. Gender as a factor in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 26-40
    Google Scholar
  • 223 Yassa R, Jones B D. The complications of tardive dyskinesia.  Psychosomatics. 1985;  26 305-318
    PubMedGoogle Scholar
  • 224 Yassa R, Nair N P V. Incidence of tardive dyskinesia in an outpatients population.  Psychosomatics. 1984;  25 479-481
    PubMedGoogle Scholar
  • 225 Yassa R, Nair N P V. Anticholinergic drugs as factors in the development of tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997: 117-125
    Google Scholar
  • 226 Yassa R, Nair N P V, Dimitry R. Prevalence of tardive dystonia.  Acta Psychiatr Scand. 1986a;  73 629-633
    PubMedGoogle Scholar
  • 227 Yassa R, Nair N P V, Schwartz G. Early versus late onset psychosis and tardive dyskinesia.  Biol Psychiatry. 1986b;  21 1291-1297
    CrossrefPubMedGoogle Scholar
  • 228 Yassa R, Nair N P V, Iskandar H. A comparison of severe tardive dystonia and severe tardive dyskinesia.  Acta Psychiatr Scand. 1989;  80 155-159
    PubMedGoogle Scholar
  • 229 Yassa R, Nair N P V, Iskandar H, Schwartz G. Factors in the development of severe forms of tardive dyskinesia.  Am J Psychiatry. 1990;  147 1156-1163
    PubMedGoogle Scholar
  • 230 Yassa R, Nair N P V, Jeste D V. Neuroleptic-induced movement disorders. Cambridge; 1st ed. Cambridge University Press 1997
    Google Scholar
  • 231 Yazici O, Kantemir E, Tastaban Y, Ocok A, Ozguroglu M. Spontaneous improvement of tardive dystonia during mania.  Br J Psychiatry. 1991;  158 847-850
    PubMedGoogle Scholar
  • 232 Youssef H A, Waddington J L. Mortality and morbidity in tardive dyskinesia: association in chronic schizophrenia.  Acta Psychiatr Scand. 1987;  75 74-77
    CrossrefPubMedGoogle Scholar

M. Maršálek

Mental Hospital Prague Bohnice

Ústavní 91

181 02 Prague 8

Czech Republic

Phone: 00420-2-84016242

Fax: 00420-2-8558097

Email: marsalek@plbohnice.cz

      >